dihydroisotanshinone i has been researched along with Experimental Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YC; Huang, WS; Kuan, FC; Lee, IY; Lin, YS; Lin, YY; Shu, LH; Wu, CY; Yang, YH | 1 |
1 other study(ies) available for dihydroisotanshinone i and Experimental Neoplasms
| Article | Year |
|---|---|
Danshen improves survival of patients with colon cancer and dihydroisotanshinone I inhibit the proliferation of colon cancer cells via apoptosis and skp2 signaling pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Movement; Cohort Studies; Colonic Neoplasms; HCT116 Cells; HT29 Cells; Humans; Mice; Neoplasms, Experimental; Phenanthrenes; RAW 264.7 Cells; RNA, Messenger; S-Phase Kinase-Associated Proteins; Salvia miltiorrhiza; Taiwan | 2017 |